Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ATNMBullishM&Anews

High materiality7/10

Actinium's Actimab-A Safety Data at ASH 2026 Could Expand AML Backbone

Nov 4, 2026, 9:10 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive safety signals and validation of Actimab-A as a backbone could attract speculative buying and reposition ATNM as a broader AML player; biotech PRs around ASH often drive short-term moves, though actual clinical impact remains uncertain.

AI summary

What happened, with direct paths to the underlying reporting

Actinium disclosed an ASH 2026 abstract evaluating long-term safety of Actimab-A with CLAG-M in relapsed/refractory AML, focusing on blood count recovery and potential kidney/liver toxicity in survivors. Earlier ASH data showed notable one- and two-year survival in venetoclax-treated and TP53-mutated subgroups, supporting Actimab-A as a mutation-agnostic backbone and potential to proceed to transplantation. The findings could catalyze expanded development and investor interest ahead of upcoming trials.

ASH 2026 abstract on Actimab-A plus CLAG-M safety in AML.
Long-term follow-up analyzes blood recovery and kidney/liver toxicity.
Prior efficacy: 1-year OS 59%, 2-year 32% (venetoclax-treated); TP53 51%/19%.
Actinium frames Actimab-A as mutation-agnostic AML backbone; supports broader use.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.